At the news
? NEUTRALIMPACT 4/10 8-K filed May 15, 2026 at 08:20 ET
Pulmatrix reported Q1 2026 results with no revenue and a net loss of $1.2M, improved from $1.8M a year ago. Cash stood at $3.3M with a going-concern qualification. The company is pursuing a merger with Eos SENOLYTIX, expected to close in Q3 2026, having raised $1M in a private placement. This is a minimal-event filing for a pre-revenue entity reliant on merger completion.
- Net loss of $1.2M for Q1 2026 vs $1.8M in Q1 2025, improvement of 35%
- Cash and equivalents of $3.3M as of March 31, 2026, down from $4.1M at year-end 2025
- Financial statements prepared on a going-concern basis
- All clinical development on hold while seeking to license or monetize assets
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access